TY - CHAP M1 - Book, Section TI - Chapter 179. Hematologic Malignancies A1 - Krakow, Elizabeth F. A1 - Fraser, Graeme A2 - McKean, Sylvia C. A2 - Ross, John J. A2 - Dressler, Daniel D. A2 - Brotman, Daniel J. A2 - Ginsberg, Jeffrey S. PY - 2012 T2 - Principles and Practice of Hospital Medicine AB - What are the “classic” clinical and basic laboratory features of each of the common hematologic malignancies? (“How do I prove the diagnosis?”)What is the natural history of each disease entity without therapy?What is the goal of treatment for each disease entity (cure, prolongation of survival, or purely palliation)?Which modalities may be employed for each disease entity (chemotherapy, immunotherapy, radiation, stem cell transplant)?What is the prognosis with therapy? How can the prognosis estimate be refined?What needs to be done to prepare the patient for therapy (to communicate risks and benefits and to reduce toxicity)?How do we assess the response?How do we monitor the patient after completion of therapy, both early on (for relapse) and later (for delayed toxicities of therapy)? SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=56208532 ER -